Nucleoside boronic acids

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F24%3A00599866" target="_blank" >RIV/61388963:_____/24:00599866 - isvavai.cz</a>
Result on the web
<a href="http://www.ccsss.cz/index.php/ccsss/issue/view/48/87" target="_blank" >http://www.ccsss.cz/index.php/ccsss/issue/view/48/87</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Nucleoside boronic acids
Original language description
Advances in the field of boron chemistry have allowed this element to be used in a range of new materials, including applications for medicine. Boron-based drugs have now been developed as therapeutic agents for cancer, and for viral, bacterial, and fungal infections. Bortezomib (Velcade®) was the first boronic acid-containing drug approved in 2003 as aproteasome inhibitor for the treatment of multiple myeloma. Several other boron-based compounds are in clinical trials, illustrating the promise of this class of chemical in drug discovery. The boronic acid group is capable of forming bonds that are substantially stronger than a typical hydrogen bond (~75 vs.~20–30 kJ/mol). The boronate group has previously been shown to bind in a mode where it ca associate with multiple amino acids all at the one time (e.g. penicillin-binding protein).
Czech name
—
Czech description
—

Project
<a href="/en/project/LX22NPO5103" target="_blank" >LX22NPO5103: National Institute of Virology and Bacteriology</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)